Project Information

The clinical trials on JUMPAIR

Thanks to the cooperation with three important hospital structures, from January 2019 we will start clinical trials on the JUMPAIR® product to demonstrate the benefits of the new project on patients with Decubitus Ulcers of stage 2 and 3.

The Azienda Sanitaria Universitaria Integrata “S. Maria della Misericordia” in Udine (Italy), the Istituto Clinico Humanitas in Milano (Italy) and the Caritas Diocesana de Coimbra (Portugal) will cooperate to this project. These structures have a great experience in the diagnosis and treatment of the decubitus ulcers and gave their full cooperation and high esteem to the JUMPAIR® project in 2016, yet.

The antidecubitus bed will be equipped with the patented massage Kinetic® Onde di Benessere, that will move the lean-points of the body moving the slats creating a continuous wave from feet to head and will be equipped with a patented ventilation system. The patients, throughout the whole period, will be constantly controlled: the evolution of the Decubitus Ulcers will be recorded and monitored from the medical staff properly trained to follow the project.

The massage, the ventilation and the movement of the different sections of the bed will be manually controlled. An intelligent software will be able, thanks to the monitoring of specific parameters, to automatically activate and deactivate the just mentioned functionalities.

The Economic Challenge

DeU has major economic costs as well as heavy casualties for Europe. In Europe, the share of European health costs on the Gross Domestic Product (GDP) was 9,2% in 2012, so €1.493 billion. In Europe, overall DeU is estimated to cost to the European Public Health System almost 0.1% of GDP for European countries, bringing annual costs to more than €16 billion. The financial cost of DeU in the EU is estimated to reach to the percentage of 1,1% of the total National Health Service (NHS) expenditure by 2020.

Market Hospital Beds

Currently, the global market for hospital beds is valued at €120,2 billion in 2015, and it is expected to high growth at a CAGR of 4,2% over the next 5 years amounting to €147,6 billion in 2020. Within the global hospital beds market, the current global market for therapeutic beds is valued at €94,6 billion, and it is expected to high growth at a CAGR of 5,7% over the next 5 years amounting to €124,9 billion in 2020. The estimated value of the European Market of therapeutic beds is of €9,6 billion in 2015 and of €12,7 billion in 2020. Spurred by the hefty bill and lack of resources, hospitals and in particular their Innovation Units are continuously looking for new strategies to minimize the incidence of DeU. Prevention and early diagnosis are the main priority with DeU. While 95% of all DeU are considered preventable, no concluding evidence exists that current devices are effective in the prevention of DeU. Indeed, 38,5% of DeU appeared while using any of current devices. Thus, the aim of this project is to take advantage of this niche market offering an innovative medical technologic device for the prevention, the early diagnosis and the suitable treatment of DeU diseases improving the living conditions of patients with reduced mobility.